The therapy with ethosomes containing 5-fluorouracil for laryngotracheal stenosis in rabbit models

Eur Arch Otorhinolaryngol. 2017 Apr;274(4):1919-1924. doi: 10.1007/s00405-016-4417-3. Epub 2016 Dec 21.

Abstract

The aim of this study is to evaluate the efficacy of ethosomes encapsulated with 5-fluorouracil (5-FU) in treatment of laryngotracheal stenosis in rabbit models. The 5-FU ethosome was prepared by the thin film hydration method, and the amorphous, size distribution and the encapsulation efficiency was investigated. The tracheal mucosa were scraped about 0.5 cm with a nylon brush to induce the scar in airway grow, then models were divided into three groups: 5-FU ethosome group, 5-FU group and saline group, drug were injected into scar of every group by paracentesis guided under endoscope, respectively. The stenosis states were observed under laryngo fiberscope immediate, 7, 14 and 21 days after administrated. Airway stenosis of 5-FU ethosome group has no significant difference when compared with 5-FU group at 7 days after administration, but 5-FU ethosome significantly reduced the airway stenosis after 21-day administration when compared with 5-FU group again and has no restenosis during the period under observation. The fact that ethosomes encapsulated with 5-FU were effective for laryngotracheal stenosis suggests that it has potential as a new method for ameliorating airway stenosis originating from granulation tissue.

Keywords: 5-Fluorouracil; Degree of airway stenosis; Ethosome; Laryngotracheal stenosis.

MeSH terms

  • Animals
  • Antimetabolites / administration & dosage*
  • Antimetabolites / therapeutic use
  • Drug Administration Schedule
  • Drug Delivery Systems
  • Female
  • Fluorouracil / administration & dosage*
  • Fluorouracil / therapeutic use
  • Injections, Intralesional
  • Laryngostenosis / drug therapy*
  • Male
  • Rabbits
  • Random Allocation
  • Tracheal Stenosis / drug therapy*
  • Treatment Outcome

Substances

  • Antimetabolites
  • Fluorouracil